MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood

Phase 4
Completed
Conditions
Hyperlipidemia
Interventions
Drug: TAK-085
Other: Not treated with omega-3-acid ethyl esters
First Posted Date
2016-07-21
Last Posted Date
2019-02-11
Lead Sponsor
Takeda
Target Recruit Count
53
Registration Number
NCT02839902

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation

Phase 4
Completed
Conditions
Hyperlipidemia
Interventions
Drug: TAK-085
First Posted Date
2016-07-06
Last Posted Date
2019-05-06
Lead Sponsor
Takeda
Target Recruit Count
37
Registration Number
NCT02824432

Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil

Completed
Conditions
Inflammatory Bowel Disease
Interventions
Other: No Intervention
First Posted Date
2016-07-04
Last Posted Date
2020-02-25
Lead Sponsor
Takeda
Target Recruit Count
407
Registration Number
NCT02822235

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
Drug: TAK-828
First Posted Date
2016-06-29
Last Posted Date
2019-07-17
Lead Sponsor
Takeda
Target Recruit Count
24
Registration Number
NCT02817516

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

Phase 3
Completed
Conditions
Back Pain
Neck Pain
Spasm
Interventions
Drug: Cyclobenzaprine HCl
Drug: Placebo
First Posted Date
2016-06-27
Last Posted Date
2019-04-08
Lead Sponsor
Takeda
Target Recruit Count
180
Registration Number
NCT02814565

A Food Effect Study of TAK-385 Final Formulation

Phase 1
Completed
Conditions
Japanese Premenopausal Healthy Adult Women
Interventions
Drug: TAK-385 40 mg
First Posted Date
2016-06-07
Last Posted Date
2017-12-18
Lead Sponsor
Takeda
Target Recruit Count
12
Registration Number
NCT02792062

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Phase 3
Completed
Conditions
Pediatric Hypertension
Interventions
Drug: Azilsartan
Drug: Placebo
First Posted Date
2016-06-06
Last Posted Date
2020-02-07
Lead Sponsor
Takeda
Target Recruit Count
27
Registration Number
NCT02791438

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

Phase 4
Completed
Conditions
Pouchitis
Interventions
Drug: Vedolizumab Placebo
Drug: Vedolizumab
Drug: Ciprofloxacin
First Posted Date
2016-06-03
Last Posted Date
2022-02-24
Lead Sponsor
Takeda
Target Recruit Count
102
Registration Number
NCT02790138
Locations
🇧🇪

UZ Leuven - University Hospital Gasthuisberg, Leuven, Belgium

🇳🇱

Academic Medical Center, Amsterdam, Netherlands

🇮🇹

Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy

and more 31 locations

A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas

Completed
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Other: No Intervention
First Posted Date
2016-06-02
Last Posted Date
2017-03-21
Lead Sponsor
Takeda
Target Recruit Count
198
Registration Number
NCT02788916

TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: TAK-438
Drug: Clarithromycin
First Posted Date
2016-05-17
Last Posted Date
2016-05-17
Lead Sponsor
Takeda
Target Recruit Count
16
Registration Number
NCT02774902
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy